We are live on
!
Find out more
Lazard Asset Management Portfolio holdings
AUM
$60.8B
1-Year Est. Return
22.47%
This Fund
S&P 500
This Quarter
Est. Return
+5.89%
1 Year Est. Return
+22.47%
3 Year Est. Return
+62.53%
5 Year Est. Return
+77.87%
10 Year Est. Return
+302.07%
AUM
$47.8B
AUM Growth
+$3.07B
(+6.9%)
Cap. Flow
-$507M
Cap. Flow
% of AUM
-1.06%
Top 10 Holdings %
Top 10 Hldgs %
17.74%
Holding
1,131
New
130
Increased
292
Reduced
306
Closed
143
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Teva Pharmaceuticals
TEVA
|
+$526M |
| 2 |
Ally Financial
ALLY
|
+$198M |
| 3 |
CSX Corp
CSX
|
+$191M |
| 4 |
NetEase
NTES
|
+$173M |
| 5 |
Norwegian Cruise Line
NCLH
|
+$171M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$262M |
| 2 |
CVS Health
CVS
|
+$240M |
| 3 |
Mastercard
MA
|
+$204M |
| 4 |
McKesson
MCK
|
+$201M |
| 5 |
Molson Coors Class B
TAP
|
+$171M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 14.83% |
| 2 | Communication Services | 13.94% |
| 3 | Technology | 12.15% |
| 4 | Financials | 10.5% |
| 5 | Energy | 9.35% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
76
Novartis
NVS
$295B
| $191M | 0.4% |
2,360,360
+92,375
| +4% | +$7.27M |
|
77
Amazon
AMZN
$2.5T
| $189M | 0.4% |
11,644,540
-659,800
| -5% | -$10.4M |
|
|
DD
78
DELISTED
Du Pont De Nemours E I
DD
| $189M | 0.4% |
3,041,485
-202,464
| -6% | -$13M |
|
|
MRO
79
DELISTED
Marathon Oil Corporation
MRO
| $187M | 0.39% |
4,692,596
+1,404,837
| +43% | +$51.8M |
|
80
CoreCivic
CXW
$3.1B
| $176M | 0.37% |
5,370,135
-78,422
| -1% | -$2.56M |
|
81
ICICI Bank
IBN
$106B
| $175M | 0.37% |
19,337,626
-1,889,124
| -9% | -$16.3M |
|
82
International Paper
IP
$22.3B
| $173M | 0.36% |
3,662,036
+578,542
| +19% | +$25.4M |
|
|
NVO
83
Novo Nordisk
NVO
$216B
| $171M | 0.36% |
7,407,818
+214,696
| +3% | +$4.74M |
|
84
Ryanair
RYAAY
$29.5B
| $168M | 0.35% |
7,321,277
+82,402
| +1% | +$1.88M |
|
|
85
Norwegian Cruise Line
NCLH
$8.89B
| $168M | 0.35% |
+5,286,936
| New | +$171M |
|
86
SPDR Gold Trust
GLD
$132B
| $167M | 0.35% |
1,304,927
-73,800
| -5% | -$9.17M |
|
|
TTM
87
DELISTED
Tata Motors Limited
TTM
| $157M | 0.33% |
4,031,989
+217,906
| +6% | +$8.37M |
|
88
SLB Ltd
SLB
$77.8B
| $156M | 0.33% |
1,322,543
+30,880
| +2% | +$3.18M |
|
89
Prudential
PUK
$36.5B
| $155M | 0.32% |
3,492,610
+198,596
| +6% | +$8.81M |
|
90
RTX Corp
RTX
$287B
| $153M | 0.32% |
2,109,655
+4,400
| +0.2% | +$324K |
|
91
AB InBev
BUD
$158B
| $151M | 0.32% |
1,314,576
-2,975
| -0.2% | -$327K |
|
92
DuPont de Nemours
DD
$18.6B
| $146M | 0.3% |
1,119,187
-671,813
| -38% | -$85.6M |
|
93
Credicorp
BAP
$30.9B
| $138M | 0.29% |
888,746
-298
| -0% | -$44.7K |
|
94
iShares Core S&P 500 ETF
IVV
$869B
| $135M | 0.28% |
684,497
+880
| +0.1% | +$168K |
|
|
NBL
95
DELISTED
Noble Energy, Inc.
NBL
| $134M | 0.28% |
1,724,159
-95,478
| -5% | -$6.95M |
|
|
JOY
96
DELISTED
Joy Global Inc
JOY
| $133M | 0.28% |
2,157,499
+79,791
| +4% | +$4.8M |
|
97
Petrobras Class A
PBR.A
$107B
| $130M | 0.27% |
8,324,220
-1,013,031
| -11% | -$15.6M |
|
|
TFCF
98
DELISTED
Twenty-First Century Fox, Inc. Class B
TFCF
| $126M | 0.26% |
+3,692,577
| New | +$122M |
|
99
Republic Services
RSG
$66.7B
| $121M | 0.25% |
3,195,326
-211,549
| -6% | -$7.5M |
|
100
Abbott
ABT
$180B
| $120M | 0.25% |
2,940,401
-148,943
| -5% | -$5.85M |
|
Similar funds
QCM
Lazard Asset Management's Q2 2014 Portfolio in Review
As of Q2 2014, Lazard Asset Management held 1,131 positions worth $47.8B, up 6.9% from $44.8B the previous quarter. Its ten largest holdings account for 18% of the portfolio.
Lazard Asset Management's Q2 2014 filing shows 130 new, 292 increased, 306 reduced and 143 closed positions. Its largest new stake was Ally Financial: 8,153,883 shares worth $195M. The largest sale was Gilead Sciences, an estimated $262M.
By sector, the portfolio is most concentrated in Healthcare at 15% of assets, down from 16% a quarter earlier, followed by Communication Services and Technology.
- Lazard Asset Management's largest Q2 2014 buy was Ally Financial: 8,153,883 shares worth $195M.
- Lazard Asset Management added most to Teva Pharmaceuticals in Q2 2014, an estimated $526M increase.
- Lazard Asset Management's biggest Q2 2014 reduction was Gilead Sciences, cutting an estimated $262M.
- Lazard Asset Management fully exited Mastercard in Q2 2014, selling an estimated $204M.
- Lazard Asset Management's ten largest holdings make up 18% of its $47.8B portfolio in Q2 2014.
- Lazard Asset Management opened 130 new positions and closed 143 in Q2 2014.
- Lazard Asset Management's portfolio value rose 6.9% quarter-over-quarter to $47.8B.
Based on Lazard Asset Management's 13F filing for Q2 2014, filed 12 Aug 2014.